×

Biotech and Pharmaceuticals Life Sciences

  • MUMBAI, Aug 22- India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in...

  • MUMBAI, Aug 22- India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in...

  • Where the solar eclipse will first make landfall

    CNBC's Jane Wells reports the latest from Madras, Oregon where the solar eclipse shadow will first make landfall.

  • FRANKFURT, Aug 21- AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros on a research alliance with German biotech start-up Ethris. In a deal with Astra and its biotech division MedImmune, Ethris will receive 25 million euros upfront, research funding and milestone...

  • Photovoltaic solar panels in a row at sunrise.

    The solar eclipse will significantly diminish solar capacity for a couple of hours, prompting the solar industry to set up a complex back-up system of other power sources, Vox reports.

  • Aug 17- The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive...

  • Aug 17- The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive...

  • MORRIS PLAINS, N.J. _ Immunomedics Inc. on Wednesday reported a loss of $53.3 million in its fiscal fourth quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share. Immunomedics shares have more than doubled since the beginning of the year.

  • TORONTO, Aug 15- Canada's main stock index slipped on Tuesday, with gains for financial stocks offset by losses for oil companies as crude prices fell. Precious metals miners also lost ground as the price of gold pulled back on easing geopolitical tensions over North Korea. Suncor Energy Inc slipped 0.4 percent to C $40.68, and Pembina Pipeline Corp fell 0.9...

  • SAN RAMON, Calif. _ Galena Biopharma Inc. on Monday reported a second-quarter loss of $8.4 million, after reporting a profit in the same period a year earlier. The San Ramon, California- based company said it had a loss of 22 cents per share. Keywords: Galena Biopharma, Earnings Report.

  • THE WOODLANDS, Texas _ Repros Therapeutics Inc. on Monday reported a loss of $2.2 million in its second quarter. The The Woodlands, Texas- based company said it had a loss of 8 cents per share. Keywords: Repros Therapeutics, Earnings Report.

  • PALO ALTO, Calif. _ Eiger BioPharmaceuticals Inc. on Monday reported a loss of $11.1 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.38 per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • Towns in the path of the eclipse hope it will shine on bottom line

    Cities in the 70-mile-wide "Zone of Totality" are bracing for a huge influx of tourists.

  • WALTHAM, Mass. _ Syndax Pharmaceuticals Inc. on Thursday reported a loss of $13.6 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • CAMBRIDGE, Mass. _ Dicerna Pharmaceuticals Inc. on Thursday reported a loss of $15.2 million in its second quarter. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • BOSTON _ Pieris Pharmaceuticals Inc. on Wednesday reported a loss of $10.1 million in its second quarter. On a per-share basis, the Boston- based company said it had a loss of 23 cents. Keywords: Pieris Pharmaceuticals, Earnings Report.

  • NEW YORK _ Fortress Biotech Inc. on Wednesday reported a loss of $17.4 million in its second quarter. The New York- based company said it had a loss of 43 cents per share. Keywords: Fortress Biotech, Earnings Report.

  • SOUTH SAN FRANCISCO, Calif. _ Portola Pharmaceuticals Inc. on Wednesday reported a loss of $69.5 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.10 per share. Portola Pharmaceuticals shares have more than doubled since the beginning of the year.

  • RICHMOND, Calif. _ Sangamo BioSciences Inc. on Wednesday reported a loss of $12.5 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • AUSTIN, Texas _ Aeglea Biotherapeutics Inc. on Wednesday reported a loss of $6.6 million in its second quarter. On a per-share basis, the Austin, Texas- based company said it had a loss of 47 cents. Keywords: Aeglea Biotherapeutics, Earnings Report.